Cargando…

DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers

Stratification of oestrogen receptor (ER) negative and triple negative breast cancers (TNBCs) is urgently needed. In the current study, a cohort of 880 ER- (including 635 TNBCs) was immuno-profiled for a panel of DNA repair proteins including: Pol β, FEN1, APE1, XRCC1, SMUG1, PARP1, BRCA1, ATR, ATM,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Fatah, Tarek M.A., Arora, Arvind, Moseley, Paul M., Perry, Christina, Rakha, Emad A., Green, Andrew R., Chan, Stephen Y.T., Ellis, Ian O., Madhusudan, Srinivasan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673139/ https://www.ncbi.nlm.nih.gov/pubmed/26267318

Ejemplares similares

Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers?
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts()
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response
por: Barone, Giancarlo, et al.
Publicado: (2018)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2019)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk
por: Tsai, Chia-Wen, et al.
Publicado: (2018)

ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022)

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
por: Abdel-Fatah, Tarek M. A., et al.
Publicado: (2019)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era
por: Perry, Christina, et al.
Publicado: (2014)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives
por: Wright, Nikita, et al.
Publicado: (2018)

Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells
por: Sultana, Rebeka, et al.
Publicado: (2013)

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
por: Cserni, Gábor, et al.
Publicado: (2021)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Peterlongo, Paolo, et al.
Publicado: (2021)

Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

Isolation of a small molecule inhibitor of DNA base excision repair
por: Madhusudan, Srinivasan, et al.
Publicado: (2005)

Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers
por: Domagala, Pawel, et al.
Publicado: (2015)

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
por: Elsheikh, S E, et al.
Publicado: (2008)

Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
por: Ribeiro, Enilze, et al.
Publicado: (2013)

Exploiting DNA repair defects in triple negative breast cancer to improve cell killing
por: Lee, Kevin J., et al.
Publicado: (2020)

Nucleotide excision repair: a versatile and smart toolkit: Nucleotide excision repair
por: Zhang, Xiping, et al.
Publicado: (2022)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Bastiaansen, Anna E. M., et al.
Publicado: (2020)

DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms
por: Azevedo, Ana P., et al.
Publicado: (2017)

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
por: Clark, Curtis A., et al.
Publicado: (2021)

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency
por: Liao, Gaoming, et al.
Publicado: (2022)

Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair
por: Matta, Jaime, et al.
Publicado: (2017)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers
por: Ogden, Angela, et al.
Publicado: (2020)

The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks
por: Alshareeda, Alaa T., et al.
Publicado: (2018)

Negative Predictors of Outcomes of Flexor Tendon Repairs
por: Hurley, C M, et al.
Publicado: (2019)

Nucleotide Excision Repair in Caenorhabditis elegans
por: Lans, Hannes, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4i957a035j4olft6mtndegs2db